Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate

被引:0
|
作者
Tapia, Rodrigo [1 ]
Mena, Juan [1 ]
Garcia, Victoria [1 ]
Culhane, Marie [2 ]
Medina, Rafael A. [3 ,4 ,5 ]
Neira, Victor [1 ]
机构
[1] Univ Chile, Fac Ciencias Vet, Med Prevent Anim, Santiago, Chile
[2] Univ Minnesota, Coll Vet Med, Vet Populat Med, St Paul, MN USA
[3] Emory Univ, Sch Med, Dept Pathol & Expt Med, Atlanta, GA USA
[4] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY USA
[5] Pontificia Univ Catolica Chile, Escuela Med, Dept Enfermedades Infecciosas Inmunol Pediat, Santiago, Chile
关键词
influenza; swine; vaccine; cross-protection; guinea pig model; surrogate; NEURAMINIDASE; TRANSMISSION;
D O I
10.3389/fvets.2023.1245278
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Influenza A virus poses a significant threat to public health and the swine industry. Vaccination is the primary measure for controlling the disease, but the effectiveness of vaccines can vary depending on the antigenic match between vaccine strains and circulating strains. In Chile, H1N1pdm09 and other lineages H1N2 and H3N2 have been detected in pigs, which are genetically distinct from the strains included in commercial vaccines. This study aimed to evaluate the cross-protection by commercial vaccines against strains circulating in Chile using the guinea pig model. For this study, four circulating strains [A/swine/Chile/H1A-7/2014(H1N2), A/swine/Chile/H1B-2/2014(H1N2), A/swine/Chile/H1P-12/2015(H1N1), and A/swine/Chile/H3-2/2015(H3N2)] were selected. Guinea pigs were divided into vaccinated and control groups. The vaccinated animals received either a multivalent antigenically heterologous or monovalent homologous vaccine, while the control animals remained unvaccinated. Following vaccination, all animals were intranasally challenged, and nasal wash samples were collected at different time points post-infection. The results showed that the homologous monovalent vaccine-induced hemagglutinin-specific antibodies against the Chilean pandemic H1N1pdm09 strain. However, the commercial heterologous multivalent vaccine failed to induce hemagglutinin-specific antibody titers against the H1N2 and H3N2 challenge strains. Furthermore, the homologous monovalent vaccine significantly reduced the duration of viral shedding and viral titers specifically against the Chilean pandemic H1N1pdm09 strain and heterologous multivalent vaccine only partial. These findings highlight the importance of regularly updating vaccine strains to match the circulating field strains for effective control of swine influenza. Further research is needed to develop vaccines that confer broader protection against diverse strains of swine influenza A virus.
引用
收藏
页数:7
相关论文
共 44 条
  • [41] An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus
    Leung, Ho-Chuen
    Chan, Chris Chung-Sing
    Poon, Vincent Kwok-Man
    Zhao, Han-Jun
    Cheung, Chung-Yan
    Ng, Fai
    Huang, Jian-Dong
    Zheng, Bo-Jian
    EMERGING MICROBES & INFECTIONS, 2015, 4
  • [42] Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model
    Opriessnig, Tanja
    Gauger, Phillip C.
    Gerber, Priscilla F.
    Castro, Alessandra M. M. G.
    Shen, Huigang
    Murphy, Lita
    Digard, Paul
    Halbur, Patrick G.
    Xia, Ming
    Jiang, Xi
    Tan, Ming
    PLOS ONE, 2018, 13 (01):
  • [43] Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets
    Kim, Ki-Hye
    Bhatnagar, Noopur
    Subbiah, Jeeva
    Liu, Rong
    Pal, Surya Sekhar
    Raha, Jannatul Ruhan
    Grovenstein, Phillip
    Shin, Chong Hyun
    Wang, Bao-Zhong
    Kang, Sang-Moo
    VIROLOGY, 2024, 595
  • [44] Antibodies and CD4+ T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain
    Droebner, Karoline
    Haasbach, Emanuel
    Fuchs, Cordula
    Weinzierl, Andreas O.
    Stevanovic, Stefan
    Buettner, Mathias
    Planz, Oliver
    VACCINE, 2008, 26 (52) : 6965 - 6974